Pharvaris NV logo

Pharvaris NV

PHVS
Healthcare|Biotechnology|Netherlands
$35.02
-0.86 (-2.39%)
Tangible Book
$4.18
Earnings Power
$4.31

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 42.11, 201.48, 436.06, 712.14 ], "ebit_estimate": [ -220.11, -197.6, -58.95, 89.43, 335.83 ], "ebitda_estimate": [ -210.78, -179.86, -30.54, 210.04, 453.7 ], "net_income_estimate": [ -214.08, -193.32, -88.35, 110.46, 343.41 ], "per_share_eps_estimate": [ -2.97, -2.68, -1.14, 1.38, 4.39 ], "eps_nri_estimate": [ -2.98, -2.68, -1.1, 1.38, 4.39 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 4.67, 1.88, 1.4, null, null ], "pretax_income_estimate": [ -212.96, -191.46, -88.64, 96.9, 344 ], "operating_cash_flow_per_share_estimate": [ -2.04, -1.2, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -56.85, -62.63, -31.59, null, null ], "gross_margin_estimate": [ 100, 79, 82.33, 86, 92 ], "operating_cash_flow_estimate": [ -133.47, -78.29, null, null, null ], "pettm_estimate": [ 0, 0, 0, 25.32, 7.98 ], "long_term_growth_rate_mean": 29.46, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 28.6, "future_eps_nri_estimate_growth": 29.46, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 30.75, "future_ebitda_estimate_growth": 43.4, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 22.56, "future_pretax_income_estimate_growth": 22.25, "future_book_value_per_share_estimate_growth": -36.75, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 18.75, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }
quarterly
{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, 2.11, 3.79, 6.97, 18.05 ], "ebit_estimate": [ -53.24, -55.54, -62.49, -56.86, -56.18, -55.46, -41.01 ], "ebitda_estimate": [ -51.43, -53.37, -55.13, null, null, null, null ], "net_income_estimate": [ -51.6, -53.54, -56.48, -54.58, -53.9, -53.18, -38.73 ], "per_share_eps_estimate": [ -0.74, -0.75, -0.79, -0.79, -0.78, -0.76, -0.6 ], "eps_nri_estimate": [ -0.74, -0.75, -0.8, -0.79, -0.78, -0.76, -0.6 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -50.92, -53.64, -61.88, -54.58, -53.9, -53.18, -38.73 ], "operating_cash_flow_per_share_estimate": [ -1.47, -2.26, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, 92, 92 ], "operating_cash_flow_estimate": [ -96.18, -147.63, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 29.46, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 28.6, "future_eps_nri_estimate_growth": 29.46, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 30.75, "future_ebitda_estimate_growth": 43.4, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 22.56, "future_pretax_income_estimate_growth": 22.25, "future_book_value_per_share_estimate_growth": -36.75, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 18.75, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

News

2026-07-02 02:02:26
2026-06-30 00:03:08
2026-06-25 18:01:27